Tarsus Pharmaceuticals Announces Appointment of New COO and CFO

Source: Tarsus Pharmaceuticals

Tarsus Pharmaceuticals announced the appointment of two pharmaceutical veterans to its executive leadership team: Sesha Neervannan, PhD, to the position of Chief Operating Officer (COO), and Leo Greenstein to the position of Chief Financial Officer (CFO). As part of its leadership, Sesha and Leo will help guide Tarsus Pharmaceuticals’ corporate and product development, leveraging their proven knowledge, capabilities, and leadership skills to help Tarsus achieve its objectives.    

“On the heels of the positive news regarding our Mars and Jupiter clinical studies, I’m both proud and excited to welcome Sesha and Leo to the Tarsus leadership team,” Tarsus CEO Bobak Azamian, MD, PhD, said in a company news release. “To successfully commercialize TP-03 and future pipeline products, Tarsus requires experienced, passionate leaders that elevate the organizations they lead. With their deep and wide therapeutics experience, both within and outside of eye care, I am confident Sesha and Leo will prove invaluable to further our mission.”

Dr. Neervannan (COO) has over 25 years of global drug development experience with novel therapeutics. Prior to joining Tarsus, he was a Senior Vice President of Global Pharmaceutical Development at Allergan, where he oversaw product development for small molecules and biologics, and contributed to regulatory filings, and approvals for multiple ocular, oral and dermal product candidates. These candidates included novel intra-ocular, sustained-release injectables (Ozurdex, Durysta), a multidose non-preserved drug product in a novel container-closure delivery system (Restasis Multidose), topical dermal products (Rhofade Cream, Aczone Gel 7.5%) and several Rx and OTC topical ophthalmic products. Prior to joining Allergan in 2007, Sesha was Director, Pharmaceutics R&D, at Amgen Inc., where he oversaw CMC functions and assisted in building the pharmaceutics organization, primarily focusing on the discovery-development interface to enable pipeline advancement.

Mr. Greenstein (CFO) has more than 20 years of business and financial experience in the development of high-growth life science companies. Prior to joining Tarsus, he served in finance roles at several publicly-traded companies in the molecular diagnostics, medical device, and pharmaceutical sectors, most recently as Senior Vice President of Finance & Corporate Controller at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) since 2013.  In these roles he was responsible for leading financial planning & analysis, treasury management, world-wide accounting operations, stock-plan administration, tax planning and compliance, and SEC matters. Leo has played significant roles in the assessment and completion of numerous fundraises, investor relations initiatives, and business development activities; and is a California-licensed attorney and CPA.


Related Content